AU2003269962A1 - Antisense modulation of acyl-coa synthetase 1 expression - Google Patents
Antisense modulation of acyl-coa synthetase 1 expressionInfo
- Publication number
- AU2003269962A1 AU2003269962A1 AU2003269962A AU2003269962A AU2003269962A1 AU 2003269962 A1 AU2003269962 A1 AU 2003269962A1 AU 2003269962 A AU2003269962 A AU 2003269962A AU 2003269962 A AU2003269962 A AU 2003269962A AU 2003269962 A1 AU2003269962 A1 AU 2003269962A1
- Authority
- AU
- Australia
- Prior art keywords
- acyl
- expression
- coa synthetase
- antisense modulation
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101000799318 Homo sapiens Long-chain-fatty-acid-CoA ligase 1 Proteins 0.000 title 1
- 102100033995 Long-chain-fatty-acid-CoA ligase 1 Human genes 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
- C12Y602/01—Acid-Thiol Ligases (6.2.1)
- C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40359102P | 2002-08-14 | 2002-08-14 | |
| US60/403,591 | 2002-08-14 | ||
| PCT/US2003/025389 WO2004016749A2 (fr) | 2002-08-14 | 2003-08-14 | Modulation antisens de l'expression de l'acyl-coa synthetase 1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003269962A1 true AU2003269962A1 (en) | 2004-03-03 |
| AU2003269962A8 AU2003269962A8 (en) | 2004-03-03 |
Family
ID=31888248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003269962A Abandoned AU2003269962A1 (en) | 2002-08-14 | 2003-08-14 | Antisense modulation of acyl-coa synthetase 1 expression |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1572713A4 (fr) |
| JP (1) | JP2006506976A (fr) |
| AU (1) | AU2003269962A1 (fr) |
| BR (1) | BR0313550A (fr) |
| CA (1) | CA2495037A1 (fr) |
| MX (1) | MXPA05001837A (fr) |
| WO (1) | WO2004016749A2 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2609180A1 (fr) * | 2005-05-24 | 2006-11-30 | Isis Pharmaceuticals, Inc. | Compositions et utilisations dans la lmw-ptpase |
| JPWO2010079819A1 (ja) * | 2009-01-08 | 2012-06-28 | 塩野義製薬株式会社 | 肥満または糖尿病治療用医薬組成物 |
| JP2015082971A (ja) * | 2012-02-10 | 2015-04-30 | 国立大学法人大阪大学 | Acsl1に対するアンチセンスオリゴヌクレオチド |
| WO2015020194A1 (fr) * | 2013-08-09 | 2015-02-12 | 国立大学法人大阪大学 | Oligonucléotide antisens contre acsl1 |
| US11638717B2 (en) | 2017-03-29 | 2023-05-02 | Shionogi & Co., Ltd. | Complex of nucleic acid medicine and multibranched lipid |
| EP4005602A4 (fr) | 2019-07-30 | 2024-06-12 | Shionogi & Co., Ltd | Médicament à base d'acide nucléique ciblant le murf1 |
| JP7751302B2 (ja) | 2020-06-15 | 2025-10-08 | リードファーマ株式会社 | 架橋型ヌクレオシドおよびヌクレオチド |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US20030138832A1 (en) * | 2001-12-19 | 2003-07-24 | Kadyk Lisa C. | Modulating insulin receptor signaling through targeting FACL |
-
2003
- 2003-08-14 MX MXPA05001837A patent/MXPA05001837A/es not_active Application Discontinuation
- 2003-08-14 WO PCT/US2003/025389 patent/WO2004016749A2/fr not_active Ceased
- 2003-08-14 CA CA002495037A patent/CA2495037A1/fr not_active Abandoned
- 2003-08-14 JP JP2004529376A patent/JP2006506976A/ja not_active Ceased
- 2003-08-14 BR BRPI0313550-0A patent/BR0313550A/pt not_active Application Discontinuation
- 2003-08-14 AU AU2003269962A patent/AU2003269962A1/en not_active Abandoned
- 2003-08-14 EP EP03751855A patent/EP1572713A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05001837A (es) | 2005-04-19 |
| AU2003269962A8 (en) | 2004-03-03 |
| EP1572713A4 (fr) | 2006-05-24 |
| JP2006506976A (ja) | 2006-03-02 |
| WO2004016749A3 (fr) | 2004-08-26 |
| BR0313550A (pt) | 2006-06-13 |
| EP1572713A2 (fr) | 2005-09-14 |
| WO2004016749A2 (fr) | 2004-02-26 |
| CA2495037A1 (fr) | 2004-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003281327A1 (en) | Antisense modulation of tfg-beta 2 expression | |
| AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
| AU2002227435A1 (en) | Antisense modulation of calreticulin expression | |
| AU2002350228A1 (en) | Antisense modulation of myd88 expression | |
| AU2003268096A1 (en) | ANTISENSE MODULATION OF Nav1.3 EXPRESSION | |
| AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
| AU2002366788A1 (en) | Antisense modulation of ship-1 expression | |
| AU2002318139A1 (en) | Antisense modulation of src-c expression | |
| AU2001288968A1 (en) | Antisense modulation of btak expression | |
| AU2003257966A1 (en) | Antisense modulation of lar expression | |
| AU2002357102A1 (en) | Antisense modulation of cd36l1 expression | |
| AU2003269962A1 (en) | Antisense modulation of acyl-coa synthetase 1 expression | |
| AU2001234461A1 (en) | Antisense modulation of daxx expression | |
| AU2002347809A1 (en) | Antisense modulation of inhibitor-kappa b kinase-gamma expression | |
| AU2003254258A1 (en) | Antisense modulation of edg1 expression | |
| AU2003241496A1 (en) | Antisense modulation of inhibitor-kappa b kinase-beta expression | |
| AU2003287180A1 (en) | Antisense modulation of gfat expression | |
| AU2003261307A1 (en) | Antisense modulation of resistin expression | |
| AU2003230301A1 (en) | Antisense modulation of dyrk4 expression | |
| AU2002245089A1 (en) | Antisense modulation of cytohesin-1 expression | |
| AU2003247701A1 (en) | Antisense modulation of livin expression | |
| AU2003237211A1 (en) | Antisense modulation of vegf-b expression | |
| AU2003236510A1 (en) | Antisense modulation of ptpn12 expression | |
| AU2002343427A1 (en) | Antisense modulation of sphingosine-1-phosphate lyase expression | |
| AU2002367585A1 (en) | Methods of using 46828, a human acyl-coa synthetase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |